Lipigon Pharmaceuticals AB (publ) (LPGO.ST)
SEK 0.17
(-4.69%)
SEK 0.17
(-4.69%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -12.37 Million SEK | 66.68% |
| 2022 | -37.74 Million SEK | 8.37% |
| 2021 | -41.19 Million SEK | -426.47% |
| 2020 | -7.82 Million SEK | -58.57% |
| 2019 | -4.93 Million SEK | -30.94% |
| 2018 | -3.76 Million SEK | 99.88% |
| 2017 | -3.03 Billion SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -325 Thousand SEK | 95.18% |
| 2024 Q1 | -7.41 Million SEK | 0.13% |
| 2023 FY | -12.57 Million SEK | 66.68% |
| 2023 Q2 | 7.13 Million SEK | 204.37% |
| 2023 Q1 | -6.83 Million SEK | 25.84% |
| 2023 Q4 | -7.42 Million SEK | -52.51% |
| 2023 Q3 | -4.86 Million SEK | -168.24% |
| 2022 Q3 | -6.84 Million SEK | 45.9% |
| 2022 Q4 | -9.21 Million SEK | -34.64% |
| 2022 Q2 | -12.65 Million SEK | -40.14% |
| 2022 Q1 | -9.02 Million SEK | 37.44% |
| 2022 FY | -37.74 Million SEK | 8.37% |
| 2021 FY | -41.19 Million SEK | -426.47% |
| 2021 Q2 | -10.37 Million SEK | -112.38% |
| 2021 Q4 | -14.43 Million SEK | -25.52% |
| 2021 Q1 | -4.88 Million SEK | -3.94% |
| 2021 Q3 | -11.49 Million SEK | -10.83% |
| 2020 Q1 | -891 Thousand SEK | 0.0% |
| 2020 FY | -7.82 Million SEK | -58.57% |
| 2020 Q4 | -4.7 Million SEK | -613.2% |
| 2020 Q3 | -659 Thousand SEK | 57.78% |
| 2020 Q2 | -1.56 Million SEK | -75.2% |
| 2019 FY | -4.93 Million SEK | -30.94% |
| 2018 FY | -3.76 Million SEK | 99.88% |
| 2017 FY | -3.03 Billion SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -248.98 Million SEK | 95.031% |
| Ziccum AB (publ) | -21.56 Million SEK | 42.621% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | 24.572% |
| BioArctic AB (publ) | 252.64 Million SEK | 104.897% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -1364.024% |
| Mendus AB (publ) | -100.65 Million SEK | 87.709% |
| Genovis AB (publ.) | 54.22 Million SEK | 122.815% |
| Intervacc AB (publ) | -93.57 Million SEK | 86.78% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | 20.249% |
| Active Biotech AB (publ) | -46.48 Million SEK | 73.387% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 168.693% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | 77.677% |
| Aptahem AB (publ) | -10.1 Million SEK | -22.427% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 96.152% |
| Kancera AB (publ) | -65.04 Million SEK | 80.98% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | 90.81% |
| Fluicell AB (publ) | -26.87 Million SEK | 53.975% |
| Saniona AB (publ) | -81.06 Million SEK | 84.739% |
| Biovica International AB (publ) | -126.07 Million SEK | 90.187% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | 70.895% |
| AcouSort AB (publ) | -17.48 Million SEK | 29.256% |
| Xintela AB (publ) | -57.23 Million SEK | 78.387% |
| Abliva AB (publ) | -96.54 Million SEK | 87.187% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 96.191% |
| Karolinska Development AB (publ) | -3.5 Million SEK | -252.953% |
| OncoZenge AB (publ) | -15.9 Million SEK | 22.205% |
| Amniotics AB (publ) | -29.07 Million SEK | 57.448% |
| 2cureX AB (publ) | -36.36 Million SEK | 65.979% |
| CombiGene AB (publ) | -36.3 Million SEK | 65.925% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | 15.499% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 96.782% |
| Camurus AB (publ) | 532.35 Million SEK | 102.324% |
| Corline Biomedical AB | -1.78 Million SEK | -591.89% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | 93.156% |
| Isofol Medical AB (publ) | -41.68 Million SEK | 70.321% |
| I-Tech AB | 24.43 Million SEK | 150.628% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 98.431% |
| Cyxone AB (publ) | -21.66 Million SEK | 42.888% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | 88.325% |
| Biosergen AB | -27.26 Million SEK | 54.627% |
| Cantargia AB (publ) | -290.01 Million SEK | 95.734% |
| NextCell Pharma AB | -43.17 Million SEK | 71.345% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | 93.156% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | 27.639% |
| Nanologica AB (publ) | -69.96 Million SEK | 82.318% |
| SynAct Pharma AB | -224.49 Million SEK | 94.489% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | 71.996% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | 48.356% |
| LIDDS AB (publ) | -40.67 Million SEK | 69.585% |
| Lipum AB (publ) | -37.25 Million SEK | 66.793% |
| BioInvent International AB (publ) | -369.94 Million SEK | 96.656% |
| Alzinova AB (publ) | -16.52 Million SEK | 25.124% |
| Oncopeptides AB (publ) | -253.44 Million SEK | 95.119% |
| Pila Pharma AB (publ) | -6.39 Million SEK | -93.501% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | 89.249% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | 38.572% |
| Simris Alg AB (publ) | -36.63 Million SEK | 66.232% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | 91.559% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 96.015% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | 88.846% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | -6.96% |